Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.53 |
| ▸ | MMP9 | P14780 | 10/20 | 0.53 |
| ▸ | MMP1 | P03956 | 5/20 | 0.53 |
| ▸ | MMP14 | P50281 | 5/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | BMP1 | P13497 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379841 | 0.95 | BMP1 (0.49) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL1378261 | 0.92 | BMP1 (0.48) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL1378262 | 0.92 | BMP1 (0.48) | MMP2MMP9MMP1MMP14ADAM17 | |
| SCHEMBL1380247 | 0.92 | MMP9 (0.54) | MMP2MMP9MMP14 | |
| Hydroxyamine SCHEMBL7536560 | 0.90 | MMP9 (0.55) | MMP2MMP9MMP14 | |
| SCHEMBL1377157 | 0.87 | MMP2 (0.52) | MMP2MMP9MMP14 | |
| SCHEMBL1380421 | 0.85 | MMP2 (0.54) | MMP2MMP9MMP14 | |
| SCHEMBL1380422 | 0.85 | MMP2 (0.54) | MMP2MMP9MMP14 | |
| SCHEMBL1378393 | 0.83 | MMP2 (0.48) | MMP2MMP9ADAM17TNF | |
| SCHEMBL1380883 | 0.81 | MMP2 (0.54) | MMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4750272-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | claimed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | claimed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |